Maintain Underweight; execute ~25% trim with $87.50 stop, use puts for additional bearish exposure
Maintain Underweight with a measured ~25% trim rather than the full 25-40% prescription, as four of five prior Underweight calls on this ticker leaked alpha due to structural floor conditions (rising 200 SMA, covered dividend, active deleveraging, defensive beta) repeatedly absorbing bearish catalysts. Adopt $87.50 stop (one ATR buffer below the 200 SMA) instead of trader's $84.50 to avoid intraday wick triggers in the $2.60 ATR regime. Route additional bearish expression through the $85-strike puts hedge per the 8/20 architecture, not compounding equity reduction. The 8/14 lesson is binding: aligned bearish signals should trigger reduced exposure or tighter stop rather than waiting for catalyst resolution.
| Position | Action |
|---|---|
| Current position > 0.5% NAV residual | Trim to ~25% (low end of 25-40% range), capping residual at ~0.5% NAV |
| ATR expanding, technicals broken (RSI lower-low, MACD negative widening) | Route bearish exposure through existing $85-strike puts hedge rather than further equity reduction |
| No basing confirmation at current levels ($93.02) | Do not initiate new equity exposure |
CVS Health is deeply mispriced at $93.02 with 40%+ EPS growth and $5.65B quarterly FCF, offering a high-probability contrarian entry as the stock de-coupled from fundamentals during a 15% one-month pullback from $109.92.
| Indicator | Value | Signal |
|---|---|---|
| close_50_sma | 101.65 | bearish |
| close_200_sma | 84.72 | bullish |
| close_10_ema | 95.18 | bearish |
| rsi | 34.34 | bearish |
| macd | -2.64 | bearish |
| macds | -2.04 | bearish |
| boll | 98.90 | bearish |
| atr | 2.60 | neutral |
Support: 92.35 · 87.76 · 84.72 | Resistance: 95.18 · 98.9 · 101.65
CVS is in a confirmed short- and medium-term downtrend following a ~15% correction from its July 21 high of $109.92 to the current price of $93.02. The 50 SMA at $101.65 now acts as major resistance (~9% overhead), while the 200 SMA at $84.72 remains the critical long-term support with ~9.8% cushion remaining. Momentum is decisively bearish with MACD showing a confirmed negative crossover and RSI in oversold territory at 34.34 (dipping to 28.69 on 8/11), though ATR expansion of ~27% indicates elevated volatility warranting wider stop-loss buffers of 1.5–2× ATR ($4–$5). The transaction proposal is HOLD—existing holders should monitor the 200 SMA closely for potential exit signals, while new buyers should wait for confirmed reversal signals (RSI positive divergence, MACD histogram contraction, and reclaim of the 10 EMA at $95.18) before entering.
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Confirmed daily close above $101.79 (50 SMA) on expanding volume with MACD histogram turning positive
Then: Upgrade to Hold
EV: +$18% (base case 12-month target: $110+, ~18% upside) · concedes: Near-term volatility is elevated (ATR expanded 27% from April lows to $2.60); Political/regulatory environment around PBMs remains uncertain; Macro headwinds could delay fundamental re-rating; Short-term technicals (below 50 SMA, MACD negative) are valid concerns
The bull is confusing base effects with momentum, mistaking a one-quarter normalization for a structural inflection while every short- and medium-term timeframe shows a confirmed downtrend with momentum, breadth, and institutional flow all working against the stock.
· concedes: Dividend is intact and FCF is positive; 200 SMA at $84.72 hasn't broken as support yet; Q2 2026 did show Aetna margin recovery (one quarter); FCF yield of 6.8% is fair-to-cheap, not wildly expensive; Higher-for-longer rates do support float income on the insurance float
→ vs conservative: The conservative bull case built on 2.84% dividend yield, forward P/E of 10.9x, PEG of 0.25, and defensive beta of 0.60 is 'a foundation of sand' — the P/E requires five concurrent execution assumptions that Q3 2025 goodwill impairment proved can blow up quickly
→ vs neutral: The neutral 'hold with bullish bias, scale in on weakness' position creates the illusion of safety while maximizing downside exposure — waiting for 200 SMA at $84.72 to be tested means potentially locking in another 9% of losses before reacting, which is 'hope, not risk management'
Market Cap
$118.97 B
Share Price
~$93
52-Week Range
$69.51–$110.68
P/E TTM
24.54
Forward P/E
10.93
PEG Ratio
0.25
P/B
1.49
EPS TTM
$3.79
Forward EPS
$8.51
Dividend Yield
2.84%
Beta
0.60
Q2 2026 Revenue
$106.10 B
Q2 2026 Gross Profit
$15.75 B
Q2 2026 Operating Income
$4.70 B
Q2 2026 Net Income
$2.98 B
Q2 2026 Diluted EPS
~$2.33
Q1 2026 Revenue
$100.43 B
Q1 2026 Net Income
$2.94 B
Q1 2026 Diluted EPS
$2.30
Q3 2025 Net Income
($3.98) B
Q3 2025 Diluted EPS
($3.13)
Q3 2025 Impairment
$5.7 B
TTM Revenue
~$412 B
Operating Margin TTM
3.86%
Net Margin TTM
1.18%
Q2 2026 Total Assets
$253.8 B
Q2 2026 Total Liabilities
$173.9 B
Q2 2026 Stockholders' Equity
$79.7 B
Q2 2026 Total Debt
$76.3 B
Q2 2026 Net Debt
$50.1 B
Q2 2026 Cash & ST Investments
$13.96 B
Q2 2026 Goodwill & Intangibles
$110.1 B
Tangible Book Value
($30.4) B
Debt-to-Equity
95.5x
Current Ratio
0.87
Working Capital
($11.7) B
Q2 2026 Operating Cash Flow
$6.35 B
Q2 2026 CapEx
($0.69) B
Q2 2026 Free Cash Flow
$5.65 B
TTM Free Cash Flow
$8.08 B
Annual Dividend
~$3.4 B
Annual CapEx
~$3 B
ROE
6.2%
ROA
3.0%
2021 Revenue
~$280 B
50-Day Moving Average
$102
200-Day Moving Average
$86
Strengths
Concerns
CVS Health Corporation is a vertically integrated healthcare services company operating CVS Caremark (PBM), Aetna (insurance), CVS Pharmacy (~9,000+ stores), and primary care assets (MinuteClinic, Oak Street Health, Signify Health). The company shows clear operational and financial stabilization in 2026 following the Q3 2025 goodwill impairment ($5.7B) and MLR pressure of late 2025, with Q1-Q2 2026 net income rebounding to ~$2.94-2.98B per quarter. Valuation appears attractive on forward metrics (Forward P/E ~10.9, PEG 0.25) versus distorted trailing metrics (P/E TTM 24.54), though structural risks including PBM regulation, thin margins, negative tangible book value, and $76.3B in debt remain concerns. The setup is described as constructive but not without risk; patient accumulation is favored over aggressive buying until forward EPS delivery is confirmed.
Macro: Prediction markets price an 85% probability that the Fed delivers zero rate cuts in 2026, confirming a sustained higher-for-longer rate regime. Treasury Secretary Bessent's efforts to calm bond markets triggered a gold price spike, signaling underlying fiscal/term-premium anxiety. Equities bounced Friday 8/21 as Iran hinted at de-escalation, oil prices halted. No FRED macro series (CPI, fed funds, unemployment, 10Y Treasury) were available due to vendor API key not being configured.